RD-BIOTECH completes its biomanufacturing offer with a new production unit for DNA plasmids, raw materials for the pharmaceutical industry (GMP grade - Good Manufacturing Practices)
Winner of the France Relance 2021 prize
RD-Biotech saw the project to build its “GMP plasmids” production unit selected by the French government.
This bioproduction unit will complement our current capacities for the production of plasmid DNA, R&D grade and High-Quality grade, and will allow us to meet the growing demands of the market for new cell and gene therapies requiring plasmid DNA as biological starting material:
- Gene therapy – Therapeutic viruses: applications in oncology, hereditary diseases, …
- Gene therapy – CAR T Cells: applications in oncology, leukaemia
- Therapeutic mRNAs: applications in oncology, autoimmune diseases, vaccines including covid-19 vaccines
Currently, RD-Biotech offers 3 levels of expertise:
Molecular biology: design and construction of plasmids
Production of plasmids, R&D grade
Production of plasmids, “High Quality” grade
And soon a 4th level of expertise
Production of plasmids, "GMP" grade (BPF)
Opening of this new unit is scheduled mid-2023, in the TEMIS Santé technology park, Besançon (France):
- More than 1,200 square meters of GMP Grade laboratories
- Several independent production suites
Coming soon, our GMP grade DNA plasmid production unit providing support for our customers from the R&D phases to the commercial phases of advanced therapy drug production.
To find out more and stay informed: